Orchid Pharma-Dhanuka Laboratories merger takes effect on July 10, 2026
Orchid Pharma’s merger scheme with Dhanuka Laboratories became effective on July 10, 2026, resulting in Dhanuka Laboratories being dissolved and all its assets, liabilities and business transferring to Orchid Pharma. Following the amalgamation, Orchid Pharma’s authorized share capital increased to ₹164,51,00,000 and the company set July 23 as the record date for issuing shares under a 161:5 exchange ratio (face value ₹10:₹100). Orchid Pharma also said it has signed an exclusive supply agreement with Russia’s Pharmasyntez for Exblifep, with a potential value of USD 178 million.